EUVIMEDScopri EUVIMED
ÜbersichtsarbeitVideo/Audio

Traditional Chinese Medicine Modulation of the Gut–Liver Axis: From Barrier Disruption to Inflammasome Activation in MASLD/MASH

Lianjie Ren, Qin He, Zhuyuan Hu, Jinjin Jin, Feibao Tao

Journal of Visualized Experiments · 2026

DOI: 10.3791/70259 ↗

At a glance

Übersichtsarbeit in Journal of Visualized Experiments, 2026. Written by Lianjie Ren and 4 co-authors. Institution: Department of Traditional Chinese Medicine, Affiliated Jinhua Hospital, Zhejiang University School of Medicine. Major MEDLINE topics: Inflammasomes, Medicine, Chinese Traditional, Liver, Non-alcoholic Fatty Liver Disease. Cited 2 times so far (Crossref); 106 references.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its inflammatory-fibrotic phenotype (MASH) exhibit pronounced immunometabolic coupling. This review synthesizes evidence along the gut-liver axis, from epithelial tight-junction and gut vascular barrier (GVB) failure to TLR4-MyD88/TRIF-NF-κB amplification and NLRP3 inflammasome activation and outlines the logic of the gut-derived exposure spectrum-lipopolysaccharide (LPS), endogenous ethanol, bile acids (BAs), short-chain fatty acids (SCFAs), and trimethylamine N-oxide (TMAO). We position BA-FXR/TGR5, SCFAs-GPR41/43, and AMPK/Nrf2 as upstream/downstream modulators that reset inflammatory thresholds and confer stage-dependent druggability. Based on node-to-pathway mapping, we summarize mechanisms and translational signals for berberine (BBR), Qushihuayu (QSHY), Da-Chai-Hu Decoction (DCHD), and polysaccharides (e.g., Astragalus, Ganoderma), emphasizing pharmacokinetic and site-of-exposure constraints that support "gut-first" actions. We propose a minimal companion biomarker set-LBP/sCD14, BA profiles with FGF19-C4 dynamics, and IL-1β/GSDMD-N-paired with hierarchical imaging gates (≥30% relative MRI-PDFF decline; MRE/ELF) to underpin response typing and go/no-go decisions. Finally, we highlight critical gaps (direct human GVB readouts; longitudinal multi-omics bridged to clinical outcomes) and outline a biomarker-driven multi-arm multi-stage (MAMS) pathway for adaptive, stratified development of multi-target traditional medicine interventions in MASLD/MASH.

Subjects

MeSH terms (MEDLINE)

InflammasomesMedicine, Chinese TraditionalLiverNon-alcoholic Fatty Liver DiseaseDrugs, Chinese HerbalHumansAnimalsIntestinal Barrier Function

Substances

InflammasomesDrugs, Chinese Herbal

Authors and institutions

  • Department of Traditional Chinese Medicine, Affiliated Jinhua Hospital, Zhejiang University School of Medicine.
  • Department of Traditional Chinese Medicine, Affiliated Jinhua Hospital, Zhejiang University School of Medicine; zykrenlj@163.com.

Cite

APA

Ren, L., He, Q., Hu, Z., Jin, J., & Tao, F. (2026). Traditional Chinese Medicine Modulation of the Gut–Liver Axis: From Barrier Disruption to Inflammasome Activation in MASLD/MASH. Journal of Visualized Experiments. https://doi.org/10.3791/70259

Vancouver

Ren L, He Q, Hu Z, Jin J, Tao F. Traditional Chinese Medicine Modulation of the Gut–Liver Axis: From Barrier Disruption to Inflammasome Activation in MASLD/MASH. Journal of Visualized Experiments. 2026. doi:10.3791/70259

BibTeX
@article{Ren2026,
  author = {Ren, Lianjie and He, Qin and Hu, Zhuyuan and Jin, Jinjin and Tao, Feibao},
  title = {Traditional Chinese Medicine Modulation of the Gut–Liver Axis: From Barrier Disruption to Inflammasome Activation in MASLD/MASH},
  journal = {Journal of Visualized Experiments},
  year = {2026},
  doi = {10.3791/70259}
}
Start for free →